Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD

American Journal of Kidney Diseases

Volumn 46, Issue 5, 2005, Pages 799-811

  Levin, Adeera ^a   Djurdjev, Ognjenka ^b   Thompson, Christopher ^b   Barrett, Brendan ^b   Ethier, Jean ^b   Carlisle, Euan ^b   Barre, Paul ^b   Magner, Peter ^b   Muirhead, Norman ^b   Tobe, Sheldon ^b   Tam, Paul ^b   Wadgymar, Jose Arturo ^b   Kappel, Joanne ^b   Holland, David ^b   Pichette, Vincent ^b   Shoker, Ahmed ^b   Soltys, George ^b   Verrelli, Mauro ^b   Singer, Joel ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE

Author keywords

Anemia; Chronic kidney disease (CKD); Erythropoietin therapy; Left ventricular hypertrophy; Randomized controlled trial

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; IRON; PARATHYROID HORMONE; PHOSPHATE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMOGLOBIN DETERMINATION; HUMAN; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; OUTCOMES RESEARCH; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM; CANADA; CHRONIC DISEASE; EPOETIN ALFA; FEMALE; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HEMOGLOBINS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY DISEASES; LIPIDS; MALE; MIDDLE AGED; ORGAN SIZE; PARATHYROID HORMONE; PHOSPHATES; RENAL DIALYSIS; SINGLE-BLIND METHOD; TREATMENT FAILURE;

EID: 27144539133     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2005.08.007     Document Type: Article

References (19)

1. C. Baigent, K. Burbury, D. Wheeler Premature cardiovascular disease in chronic renal failure Lancet 356 2000 147 152
2. M.J. Landray, J. Thambyrajah, F.J. McGlynn Epidemiological study of cardiovascular risk factors in a cohort of patients with chronic renal impairment Am J Kidney Dis 38 2001 537 546
3. R.N. Foley, P.S. Parfrey, J.D. Harnett Clinical and echocardiographic disease in patients starting end stage renal disease therapy Kidney Int 47 1995 186 192
4. J.S. Silberberg, P.E. Barre, S. Prichard, A.D. Sniderman Impact of left ventricular hypertrophy on survival in end stage renal disease Kidney Int 6 1989 286 290
5. P.S. Parfrey, J.D. Harnett, S.M. Griffiths The clinical course of left ventricular hypertrophy in dialysis patients Nephron 55 1990 114 120
6. A. Levin, J. Singer, C.R. Thompson, H. Ross, M. Lewis Prevalent left ventricular hypertrophy in the predialysis population Identifying opportunities for intervention Am J Kidney Dis 27 1996 347 354
7. A. Levin, C.R. Thompson, J. Ethier Left ventricular mass index increase in early renal disease Impact of decline in hemoglobin Am J Kidney Dis 34 1999 125 134
8. R.B. Devereux, D.R. Alonso, E.M. Lutas Echocardiographic assessment of left ventricular hypertrophy Comparison to necropsy findings Am J Cardiol 57 1989 450 458
9. N.B. Schiller, P.M. Shah, M. Crawford American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms Recommendations for quantitation of the left ventricle by two-dimensional echocardiography J Am Soc Echocardiogr 2 1989 358 367
10. A.S. Levey, T. Greene, J.S. Kusek, G.J. Beck A simplified equation to predict glomerular filtration rate from serum creatinine J Am Soc Nephrol 11 2000 0828A (abstr)
11. L.E. Chambles, J.R. Roeback Methods for assessing difference between groups in change when initial measurement is subject to intra-individual variation Stat Med 12 1993 1213 1237
12. J. Twisk, K. Proper Evaluation of the results of a randomized controlled trial How to define changes between baseline and follow-up J Clin Epidemiol 57 2004 223 228
13. S.D. Roger, L.P. McMahon, A. Clarkson Impact of early and late intervention with epoetin alpha on left ventricular mass in chronic kidney disease J Am Soc Nephrol 15 2003 148 156
14. L.P. McMahon, S.D. Roger, A. Levin The development, prevention and potential reversal of left ventricular hypertrophy in chronic kidney disease J Am Soc Nephrol 15 2004 1640 1647
15. R.N. Foley, P.S. Parfrey, J. Morgan Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy Kidney Int 58 2000 1325 1335
16. S.C. Greaves, G. Gamble, J.F. Collins, G.A. Whalley, N.D. Sharpe Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure Am J Kidney Dis 24 1994 768 776
17. G.M. London, B. Pannier, A.P. Guerin Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis Follow-up of an interventional study J Am Soc Nephrol 12 2001 2759 2767
18. J. Mann, H.C. Gertstein, J. Pogue, J. Bosch, S. Yusef Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril The HOPE randomized trial Ann Intern Med 134 2001 629 636
19. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals A randomized placebo-controlled trial Lancet 360 2002 7 22